PKS Advisory Services’s Altimmune ALT Stock Holding History

PKS Advisory Services’s Portfolio ALT Stock Details ALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-15,100	Closed	-$54.5K	–	229
2025 Q4	$54.5K	Buy	+15,100	New	+$65.8K	0.01%	253

Other funds holding ALT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

PKS Advisory Services's ALT Position: Q1 2026 in Review

PKS Advisory Services sold out of Altimmune (ALT) in Q1 2026, closing a stake of 15,100 shares — an estimated $54.5K sold.

PKS Advisory Services first reported a position in ALT in Q4 2025 and held it in 1 quarter. The position peaked at $54.5K in Q4 2025. 173 funds tracked by Wall St. Rank hold ALT as of Q1 2026.

PKS Advisory Services reported no remaining Altimmune position as of Q1 2026 after selling out during the quarter.
PKS Advisory Services sold 15,100 Altimmune shares in Q1 2026, an estimated $54.5K.
PKS Advisory Services first reported a position in Altimmune in Q4 2025 and held it in 1 quarter.
PKS Advisory Services's Altimmune position peaked at $54.5K in Q4 2025.
173 funds tracked by Wall St. Rank held Altimmune as of Q1 2026.

Based on PKS Advisory Services's 13F filing for Q1 2026, filed 13 May 2026.